Multi-omics Market Size & Growth Forecast 2027–2036, By Segments (Product & Services, Type, Application, Platform, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Multi-omics Market size stood at USD 4.71 Billion in 2026 and is predicted to grow at 15.81% CAGR from 2027 to 2036, surpassing USD 20.44 Billion by 2036. The industry revenue for 2027 is calculated at USD 5.35 Billion.
Get more details on this report
Request Free Sample ReportMulti-omics Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 49.61%, supported by advanced biomedical research infrastructure, precision medicine investment, and growing use of integrated molecular datasets.
- Asia Pacific is expected to grow fastest as life sciences capabilities, healthcare investment, biotechnology infrastructure, and precision medicine adoption continue expanding.
Segment Momentum
- The oncology segment accounted for 29.16% of the market in 2026, driven by increasing use of multi-omics for tumor analysis, biomarker discovery, and personalized treatment development.
- Single-cell multi-omics is the fastest-growing type, holding a 69.7% market share in 2026, as demand rises for high-resolution molecular profiling to better understand disease mechanisms and cellular diversity.
Market Expansion Drivers
- Advancements in omics technologies accelerating integrated biological data analysis adoption
- Expanding personalized medicine applications driving multi-layer genomic and proteomic integration
- Rising pharmaceutical R&D digitization increasing multi-omics platform deployment in drug discovery
Leading Market Participants
- Prominent companies in the multi-omics market include Becton, Dickinson and Company (USA), Thermo Fisher Scientific Inc. (USA), Illumina Inc. (USA), Danaher Corporation (USA), Agilent Technologies Inc. (USA), QIAGEN N.V. (Germany), Bruker Corporation (USA), PerkinElmer Inc. (USA), 10x Genomics Inc. (USA), BGI Group (China)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.71 Billion
- 2027 Estimated Market Size: USD 5.35 Billion
- Projected Market Size: USD 20.44 Billion by 2036
- Growth Forecast: 15.81% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Products (Product & Services) | Single-cell Multi-Omics (Type) | Oncology (Application) | Genomics (Platform) | Pharmaceutical & Biotechnology Companies (End-use)
- Emerging Opportunity Segment: Products (Product & Services) | Single-cell Multi-Omics (Type) | Oncology (Application) | Proteomics (Platform) | Pharmaceutical & Biotechnology Companies (End-use)
Market Growth Drivers and Industry Trends
Advancements in omics technologies accelerating integrated biological data analysis adoption
Rapid improvements in sequencing, molecular profiling, and computational analysis are enabling researchers to combine multiple biological datasets, which will drive the multi-omics market growth through broader adoption of integrated analysis approaches. Scientists and healthcare researchers are increasingly using interconnected genomic, proteomic, and metabolomic information to gain deeper insights into complex biological mechanisms. Enhanced data processing capabilities are making multi-dimensional research workflows more practical across biomedical studies and clinical applications.
Expanding personalized medicine applications driving multi-layer genomic and proteomic integration
The shift toward individualized treatment strategies is increasing demand for comprehensive biological understanding, and the multi-omics market growth is propelled by the need to integrate genomic, proteomic, and other molecular information for personalized healthcare approaches. Clinicians and researchers are leveraging combined datasets to identify disease patterns, improve biomarker discovery, and support more targeted therapeutic decisions. This integration helps bridge the gap between molecular research findings and patient-specific treatment strategies.
Rising pharmaceutical R&D digitization increasing multi-omics platform deployment in drug discovery
Digital transformation across pharmaceutical research is accelerating the adoption of advanced analytical platforms, allowing the multi-omics market growth to expand as drug developers incorporate integrated molecular insights into discovery pipelines. Pharmaceutical organizations are using multi-layer biological analysis to improve target identification, understand disease pathways, and optimize research processes. The combination of digital research environments and complex biological datasets is encouraging wider deployment of multi-omics solutions in development activities.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Advancements in omics technologies accelerating integrated biological data analysis adoption | 2.3% | High | North America, Europe | High | Near Term |
| Expanding personalized medicine applications driving multi-layer genomic and proteomic integration | 2.1% | High | North America, Asia Pacific | High | Mid Term |
| Rising pharmaceutical R&D digitization increasing multi-omics platform deployment in drug discovery | 1.8% | High | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for 49.61% of the multi-omics market in 2026, reflecting strong research activity in genomics, proteomics, metabolomics, and related life sciences disciplines. The region benefits from advanced biomedical research infrastructure, substantial investment in precision medicine, and increasing use of integrated biological datasets for drug discovery and disease research. Growing demand for more comprehensive disease profiling and biomarker identification is encouraging researchers and healthcare institutions to combine multiple molecular analysis techniques, while improvements in sequencing, mass spectrometry, and bioinformatics are expanding the practical applications of multi-omics approaches.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to grow at the fastest pace, supported by expanding life sciences research capabilities, rising healthcare investment, and increasing interest in precision medicine. Improvements in biotechnology infrastructure and greater adoption of advanced molecular analysis technologies are enabling research institutions to undertake increasingly sophisticated biological studies. The growing focus on disease understanding, biomarker discovery, and development of targeted therapies is also encouraging the integration of multiple omics disciplines across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Clinical Data Integration PushThe U.S. is prioritizing multi-omics platforms that integrate genomics, proteomics, and metabolomics into clinical decision-making and drug discovery pipelines. In the U.S., adoption is driven by pharmaceutical partnerships and research hospitals building scalable bioinformatics infrastructure for translational medicine workflows.
Germany 🇩🇪
Standardized Research FrameworksGermany focuses on structured multi-omics deployment across academic and clinical research institutions, emphasizing reproducibility and standardized data protocols. Research centers in Germany are increasingly aligning omics datasets with regulated biomedical studies and precision medicine initiatives.
Japan 🇯🇵
High-Precision BioinformaticsJapan emphasizes high-precision multi-omics analysis supported by strong computational biology capabilities and integrated healthcare research systems. Institutions in Japan are investing in harmonized datasets to support biomarker discovery and disease stratification studies.
South Korea 🇰🇷
AI-Driven Omics PlatformsSouth Korea is advancing multi-omics adoption through AI-enabled analytics platforms that combine clinical datasets with high-throughput sequencing outputs. In South Korea, biotech firms and hospitals are collaborating to accelerate predictive modeling for personalized therapies.
France 🇫🇷
Translational Research FocusFrance prioritizes multi-omics applications in translational research, particularly in oncology and rare disease studies. Research hospitals in France are integrating omics technologies with national biomedical programs to improve diagnostic precision and therapy selection.
Italy 🇮🇹
Academic Collaboration NetworksItaly supports multi-omics development through academic and public research collaborations focused on disease mechanisms and biomarker identification. Institutions in Italy are increasingly linking omics datasets with clinical research initiatives across university hospitals.
Segment Leadership and Growth Trends
Multi-omics Market Share (%), by Product & Services, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct & Services Segment Analysis: Products (Largest & Fastest-Growing Segment)
The multi-omics market was led by the products segment, which accounted for 62.12% of the market share in 2026 and is also expected to remain the fastest-growing category. Strong demand for sequencing platforms, reagents, assay kits, sample preparation solutions, and analytical software continues to support the segment's leadership. Increasing adoption of integrated omics workflows in biomedical research, precision medicine, and translational studies is driving consistent investment in advanced products that enhance data quality, workflow efficiency, and reproducibility. Continuous technological innovation and expanding research activities are expected to further strengthen the segment's long-term growth.
Type Segment Analysis: Single-cell Multi-Omics (Largest & Fastest-Growing Segment)
Holding the largest share of the multi-omics market, the single-cell multi-omics segment captured 69.7% in 2026 and is also projected to be the fastest-growing type. The ability to simultaneously analyze multiple molecular characteristics at the individual cell level is transforming biological research by providing deeper insights into cellular diversity, disease mechanisms, and tissue heterogeneity. Growing demand for high-resolution molecular profiling, combined with advancements in sequencing technologies and computational analysis, is accelerating the adoption of single-cell multi-omics across research institutions and clinical applications.
Application Segment Analysis: Oncology (Largest & Fastest-Growing Segment)
The oncology segment accounted for 29.16% of the market share in 2026 and continues to lead the multi-omics market while also representing the fastest-growing application. Increasing use of integrated multi-omics approaches to understand tumor biology, identify predictive biomarkers, and support personalized treatment strategies is driving demand across oncology research and clinical development. Expanding investments in cancer genomics, precision medicine initiatives, and biomarker discovery programs are further reinforcing the segment's dominant position and sustained growth.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product & Services | Products, Services | Products | Products |
| Type | Single-cell Multi-Omics, Bulk Multi-Omics | Single-cell Multi-Omics | Single-cell Multi-Omics |
| Application | Oncology, Cell Biology, Neurology, Immunology, Others | Oncology | Oncology |
| Platform | Genomics, Transcriptomics, Proteomics, Metabolomics, Integrated Omics Platforms | Genomics | Proteomics |
| End-use | Academic and Research Organizations, Pharmaceutical & Biotechnology Companies, Hospital and Diagnostic Laboratories, Others | Pharmaceutical & Biotechnology Companies | Pharmaceutical & Biotechnology Companies |
Competitive Landscape and Market Positioning
Major players in the multi-omics market:
- Becton Dickinson and Company (USA)
- Thermo Fisher Scientific, Inc. (USA)
- Illumina, Inc. (USA)
- Danaher Corporation (USA)
- Agilent Technologies, Inc. (USA)
- QIAGEN N.V. (Germany)
- BrUKer Corporation (USA)
- PerkinElmer, Inc. (USA)
- 10x Genomics, Inc. (USA)
- BGI Group (China)
Scientific differentiation in the multi-omics market is increasingly shaped by the ability to unify diverse biological datasets into actionable insights rather than by individual analytical technologies alone. Providers are expanding beyond standalone sequencing or analytical platforms by developing integrated workflows that combine sample preparation, data processing, advanced analytics, and visualization, enabling researchers to manage growing experimental complexity. Artificial intelligence and cloud-based bioinformatics are becoming central competitive levers as customers seek faster interpretation of high-dimensional datasets and improved reproducibility across studies. As translational research and precision medicine applications mature, vendors with scalable informatics capabilities, interoperable platforms, and strong validation support are gaining an advantage in environments where data quality and analytical confidence influence purchasing decisions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Becton Dickinson and Company (USA) | |||||||
| Thermo Fisher Scientific Inc. (USA) | |||||||
| Illumina Inc. (USA) | |||||||
| Danaher Corporation (USA) | |||||||
| Agilent Technologies Inc. (USA) | |||||||
| QIAGEN N.V. (Germany) | |||||||
| Bruker Corporation (USA) | |||||||
| PerkinElmer Inc. (USA) | |||||||
| 10x Genomics Inc. (USA) | |||||||
| BGI Group (China) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| GSK | Jun-26 | GSK established a strategic partnership with a UK biotechnology firm to study liver fibrosis regression mechanisms. The collaboration integrates multi-omics capabilities to identify novel therapeutic targets, advancing GSK's precision medicine initiatives and targeted drug discovery pipeline. |
| Aram Group PJSC | May-26 | Aram Group PJSC entered into a strategic alliance with Prepaire Labs to build a biological infrastructure network in the UAE. The initiative establishes a foundation for advanced genomics and multi-omics capabilities within the regional healthcare and life sciences sectors. |
| SeekGene | Jan-26 | SeekGene commercialized a high-throughput single-cell DNA methylation and RNA multi-omics platform. The integrated system expands the company's single-cell technology portfolio, offering comprehensive multi-omics analysis capabilities for cellular research. |
| Relation Therapeutics | Dec-25 | Relation Therapeutics secured a strategic alliance with Novartis valued at up to US$1.7 billion. The partnership utilizes Relation's AI-driven multi-omics discovery platform to identify therapeutic targets for allergic diseases, representing a high-value commercial investment in precision drug discovery. |
| Illumina | Jan-25 | Illumina collaborated with NVIDIA to integrate its DRAGEN genomic analysis software into NVIDIA's accelerated computing platform via Illumina Connected Analytics. This technology integration scales computing performance and accelerates AI-driven analysis of large-scale multi-omics datasets. |
| Seer | Nov-24 | Seer executed a co-marketing agreement with Thermo Fisher Scientific to drive commercial adoption of its deep proteomics platform. The joint initiative expands market access and enhances integrated proteomics and multi-omics analytical workflows for biomedical research applications. |
| Baylor Genetics | Aug-24 | Baylor Genetics partnered with Baylor College of Medicine to establish the Medical Genetics Multi-Omics Laboratory. The joint facility expands genetic testing capabilities by integrating multi-omics into clinical diagnostic workflows and precision medicine research. |
| AtlasXomics | Jan-24 | AtlasXomics formed a commercial partnership with EpiCypher to bring spatial epigenomics assays to market. The agreement expands the availability of commercial multi-omics solutions for spatial biology research, driving technology adoption in next-generation epigenomic analysis. |
| 10x Genomics, Inc. | Sep-23 | 10x Genomics launched a high-throughput single-cell profiling kit for its Chromium Single Cell Gene Expression Flex assay. The product expands cellular characterization capabilities by enabling simultaneous detection of gene and protein expression at a larger scale. |
| Becton, Dickinson and Company | Feb-23 | Becton, Dickinson and Company launched its Rhapsody HT Xpress System, a high-throughput single-cell multiomics platform. The system delivers an eightfold increase in cell isolation and analysis throughput compared to previous systems, addressing high-capacity scientific discovery needs. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Multi-omics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood-Based Samples, Tissue Samples, Cell-Based Samples, Other Biological Samples |
| Workflow Stage | Sample Preparation, Omics Data Generation, Data Integration & Analysis |
| Testing Throughput | Low Throughput, Medium Throughput, High Throughput |
Multi-omics Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Translational Research Adoption |
|
| Biopharma Use-Case Prioritization |
|
| AI-Enabled Omics Interpretation |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of multi-omics?
What is the expected industry size of multi-omics by 2036?
How is personalized medicine influencing adoption in the multi-omics market?
Why is pharmaceutical R&D increasing investment in multi-omics platforms?
Why does the oncology application lead the multi-omics market?
Why is single-cell multi-omics the fastest-growing type in the multi-omics market?
Why did North America hold the largest share of the multi-omics market in 2026?
How is Asia Pacific emerging as a high-growth market for multi-omics?
Which organizations are considered leaders in the multi-omics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization